{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:21:50Z","timestamp":1772061710037,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To investigate ocular blood flow before and 30 minutes postinjection of antivascular endothelial growth factor agents in eyes with neovascular age-related macular degeneration and to compare the reduction rates of ocular blood flow among three groups: intravitreal faricimab injections (faricimab-treated), intravitreal brolucizumab injections (brolucizumab-treated), and intravitreal aflibercept 2 mg injections (aflibercept-treated).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective observational case series included 45 eyes of 45 Japanese patients with neovascular age-related macular degeneration treated with faricimab, brolucizumab, or aflibercept 2 mg. Ocular blood flow at the optic nerve head (ONH MV) and the choroid (choroid mean blur rate) was analyzed before and 30 minutes after injections using laser speckle flowgraphy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The mean optic nerve head MV and choroid mean blur rate decreased significantly 30 minutes postinjection by 12.0% \u00b1 15.3% and 9.7% \u00b1 8.8% in the faricimab-treated group, 9.5% \u00b1 7.9% and 18.2% \u00b1 12.9% in the brolucizumab-treated group, and 10.4% \u00b1 11.9% and 6.0% \u00b1 7.7% in the aflibercept-treated group. There were no significant differences in the reduction rates of optic nerve head MV among the three groups. However, the brolucizumab-treated group showed a greater reduction in choroid mean blur rate than the aflibercept-treated group (faricimab vs. brolucizumab:\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.161; faricimab vs. aflibercept:\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.631; brolucizumab vs. aflibercept:\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.027).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Ocular blood flow significantly decreased 30 minutes postinjection in faricimab-treated, brolucizumab-treated, or aflibercept-treated eyes with neovascular age-related macular degeneration. Brolucizumab-treated eyes showed a significantly greater reduction in choroidal blood flow than aflibercept-treated eyes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004561","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T16:00:16Z","timestamp":1751040016000},"page":"2042-2048","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["COMPARISON OF OCULAR BLOOD FLOW CHANGES AT 30 MINUTES AFTER INTRAVITREAL INJECTION OF FARICIMAB, BROLUCIZUMAB, AND AFLIBERCEPT 2 mg FOR NEOVASCULAR AGE-RELATED MACULAR"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4897-2058","authenticated-orcid":false,"given":"Nobuhiro","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Haruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Dake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Furushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251021","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R2-20251021","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific crossmab optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"R3-20251021","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1755-3768.2009.01586.x","article-title":"Use of laser speckle flowgraphy in ocular blood flow research","volume":"88","author":"Sugiyama","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"R4-20251021","first-page":"339","article-title":"Measurement of optic nerve head circulation: comparison of laser speckle and hydrogen clearance methods","volume":"40","author":"Sugiyama","year":"1996","journal-title":"Jpn J Ophthalmol"},{"key":"R5-20251021","first-page":"255","article-title":"Retinal blood-flow visualization by means of laser speckle photography","volume":"22","author":"Briers","year":"1982","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R6-20251021","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2147\/OPTH.S407249","article-title":"Decrease in ocular blood flow thirty minutes after intravitreal injections of brolucizumab and aflibercept for neovascular age-related macular degeneration","volume":"17","author":"Kato","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"R7-20251021","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0021-5155(01)00498-1","article-title":"Effects of caffeine on microcirculation of the human ocular fundus","volume":"46","author":"Okuno","year":"2002","journal-title":"Jpn J Ophthalmol"},{"key":"R10-20251021","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1111\/aos.14098","article-title":"Short-term effect on the ocular circulation induced by unilateral intravitreal injection of aflibercept in age-related maculopathy","volume":"97","author":"Mursch-Edlmayr","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"R11-20251021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.9.5.9","article-title":"Assessment of choroidal neovascularization perfusion: a pilot study with laser speckle flowgraphy","volume":"9","author":"Calzetti","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"R12-20251021","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/bjophthalmol-2019-313919","article-title":"Effects of three intravitreal injections of aflibercept on the ocular circulation in eyes with age-related maculopathy","volume":"104","author":"Mursch-Edlmayr","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R13-20251021","doi-asserted-by":"crossref","first-page":"23723","DOI":"10.1038\/s41598-021-03179-x","article-title":"Short-term changes in retinal and choroidal relative flow volume after anti-VEGF treatment for neovascular age-related macular degeneration","volume":"11","author":"Calzetti","year":"2021","journal-title":"Sci Rep"},{"key":"R14-20251021","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10792-024-03107-8","article-title":"Changes in ocular blood flow in patients with neovascular age-related macular degeneration after intravitreal injection of ranibizumab biosimilar and brolucizumab","volume":"44","author":"Takizawa","year":"2024","journal-title":"Int Ophthalmol"},{"key":"R15-20251021","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.oret.2024.07.012","article-title":"Effect of brolucizumab and aflibercept on the maximum thickness of pigment epithelial detachments and sub-retinal pigment epithelium fluid in hawk and harrier","volume":"9","author":"Khanani","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"R16-20251021","first-page":"181","article-title":"Role of endothelial nitric oxide in the regulation of the vasomotor system","volume":"46","author":"Michel","year":"1998","journal-title":"Pathol Biol (Paris)"},{"key":"R17-20251021","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1167\/iovs.10-6646","article-title":"The effect of intravitreal injection of bevacizumab on retinal circulation in patients with neovascular macular degeneration","volume":"52","author":"Fontaine","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R18-20251021","doi-asserted-by":"crossref","first-page":"17235","DOI":"10.1038\/s41598-018-35683-y","article-title":"Evaluation of optic nerve head blood flow in response to increase of intraocular pressure","volume":"8","author":"Iwase","year":"2018","journal-title":"Sci Rep"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004561","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T19:00:36Z","timestamp":1761073236000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004561","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}